TransMedics Group Inc. (TMDX) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, TMDX scores 62 out of 100, grade C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine at 15 of 20 (ROIC 18.1%; FCF yield 5.74%); Whale 13F Flow at 4 of 20 (institutional accumulation and options positioning); Insider Conviction at 17 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 10 of 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 16 of 20 (Altman Z 3.5; Piotroski F 8/9; Debt/Equity 0.5).

For a prospective investor, the pillar mix is uneven. The strongest signals are the balance sheet and insider flow, while institutional accumulation registers as weak at 4 of 20. The cash-engine score is moderate, supported by the reported ROIC and FCF yield, and the macro pillar is middling given a Beta of 1.0. The valuation tradeoff is that the stock's trailing and forward multiples sit below its EV/EBITDA level, so upside depends on sustaining the reported earnings and cash-flow improvement. The 52-week range ($60.1 – $156) indicates the stock has traded far above its current price, which underscores volatility and sentiment sensitivity. This is an educational reading of the rating, not personalized advice.

Per the Profile section, TransMedics Group Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry, with a market capitalization of $2.3B. The source data does not describe its specific products, customers, or revenue model beyond the sector and industry classification. The reported margins (gross 59.9%, operating 17.9%, net 31.4%) are per the Market Data section.

Per the recent news and catalysts feed, six items are tagged to TMDX, all flagged YELLOW with the MARKET WIRE impact label: a Yahoo Finance piece describing the stock as undervalued on current earnings; a Simply Wall St stock analysis; a GuruFocus report citing a 4.0% move and a GF Score of 72/100; a MarketBeat report referencing an average price target of $121.10; a Stock Titan notice that a 4:30 p.m. ET call will accompany the Q3 results on Nov. 5; and a Yahoo Finance stock forecast piece. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals. Risk watch items drawn from the feed are the wide 52-week range and the institutional-flow weakness in the RQD rating. The Q3 earnings call is the nearest identified catalyst.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. The only sector context available is the Health Care classification and the Beta of 1.0. An investor should note that any ripple analysis would require supply-chain and correlation data not present in this dossier.

• What are the FY 2025 cash, debt, and EPS balances that underpin the reported Altman Z-Score and Debt/Equity figures?
• What is the composition of the FY 2025 net income of $190.3M, which exceeds operating income of $108.6M?
• Which specific institutional holders and insider transactions drive the RQD whale and insider pillar scores?
• What is the basis for the $121.10 average price target cited in the news feed, and how many analysts contribute to it?
• What products, customers, and supply-chain relationships generate the reported revenue, given that the supply-chain graph is empty?